He respiratory syncytial virus (RSV) is closer to having a vaccine. The inoculations of Janssen, GSK y Pfizer are very advanced and present an efficiency that around 80 percent, according to his studies. This would mean a revolution for this pathology, which can cause a severe respiratory tract disease lower in older adults and that has taken over Spanish hospitals this winter.
On the one hand, the pharmaceutical Janssen has exposed that after the inoculation of its vaccine between the 70 and 80 percent of the participants showed a considerable efficiency. The company has demonstrated that an adenovirus serotype 26 RSV vector encoding a prefusion F (preF) protein (Ad26.RSV.preF) in combination with RSV preF protein causes humoral and cellular immunogenicity.
“After vaccination, RSV A2 neutralizing antibodies increased by a factor of 12.1 from the beginning until the 15th, a finding consistent with other immunogenicity measures“, they indicate. The main conclusion is that the Ad26.RSV.preF-RSV preF protein vaccine was immunogenic and prevented RSV-mediated lower respiratory tract disease in adults from 65 yearsfor which it is intended.
“The RSV vaccine will have an impact on public health”
On the other hand, GSK has announced the publication of positive results by one Phase III study with its candidate respiratory syncytial virus (RSV) vaccine in adults older than 60 years. According to a study published in the scientific journal New England Journal of Medicinethe efficacy of the vaccine was also found in trial participants who had associated comorbidities to a greater risk of suffering serious consequences in case of illness.
As explained by Federico Martinón-Torres, coordinator of the Vaccine Clinical Trials Unit of the Santiago de Compostela Health Research Institute, researcher and co-author of the publication, RSV often produces “mild symptoms”, but can have “devastating consequences for older adults and a global burden that may approach that of seasonal flu.” “The release of these important data shows that, for the first time, we are on the verge of having an effective vaccine that could have a significant public health impact“, he assures.
The pharmaceutical company GSK is quite advanced in this regard and it is already write down dates to inoculate this RSV vaccine. They calculate that doses can be supplied before the start of the VSR 2023-24 season in the northern hemisphere, although we will have to wait for the decisions adopted by the regulatory authorities of the United States, Europe, Japan and other countries.
Pfizer will inject the vaccine into pregnant women
For its part, Pfizer has focused on another candidate group: the pregnant. They have positive front-line data from the Phase 3 Matisse clinical trial, investigating their bivalent RSV prefusion vaccine candidate, RSVpreF, or PF-06928316, when administered to pregnant participants to help protect their offspring, according to drug sources. babies from RSV disease after birth.
“The observed efficacy for medically assisted severe lower respiratory tract disease was 81.8 percent during the first 90 days of life. A substantial efficacy of 69.4 percent was demonstrated in infants during the six-month follow-up period,” they specify.
It would be the first vaccine that protect newborns against severe RSV-related respiratory diseases immediately after birth. “These data reinforce Pfizer’s determination to bring our expertise in research and development of innovative vaccines to address critical public health needs using new approaches and technologies. We look forward to working with the FDA and other regulatory agencies to bring this vaccine candidate to mothers-to-be to help protect their babies against severe RSV during the first six months of life most vulnerable, who have the highest burden of RSV disease in infants,” says Annaliesa Anderson, senior vice president and chief scientific officer, Vaccine Research and Development at Pfizer.
Although it may contain statements, data or notes from health institutions or professionals, the information contained in Redacción Médica is edited and prepared by journalists. We recommend to the reader that any health-related questions be consulted with a health professional.
